Skip to main content

Table 1 Clinical and microbiological characteristics of 28 breakthrough VSB cases

From: Breakthrough viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients receiving levofloxacin prophylaxis in a Japanese hospital

Characteristics No.
Median age (range) 55 (20–71)
Gender  
  Male 15 (53.6 %)
  Female 13 (46.4 %)
Hematological disorder  
 Myeloid malignancy  
  AML 3 (10.7 %)
  MDS overt AML 6 (21.4 %)
  MDS 8 (28.6 %)
  CML 1 (3.6 %)
 Lymphoid malignancy  
  ALL 5 (17.9 %)
  NHL 1 (3.6 %)
  T-PLL 1 (3.6 %)
 Others  
  Others 3 (10.7 %)
Hematopoietic stem cell transplantation  
  CBT 22 (78.6 %)
  rPBSCT 4 (14.3 %)
  uBMT 2 (7.1 %)
Status of the patients  
  Nosocomial infection 28 (100 %)
  Severe neutropenia (ANCs <100/pL ) 28 (100 %)
  Receipt of beta-lactam in the previous 30 day 6 (21.4 %)
Clinical presentation  
  Median body temperature (range) (°C) 38.6 (37.5-40.6)
  Acute respiratory distress syndrome 0
  Co-infection 9 (32.1 %)
Co-infectious pathogen  
  Staphylococcus epidermidis 5
  Corynebacterium striatum 2
  Enterococcus faecium 1
  Rothia mucilaginosa 1
  Escherichia coli 1
Treatment  
  Cefepime 26 (92.9 %)
  Piperacillin/tazobactam 2 (7.14 %)
  Empiric VCM administration 4 (14.3 %)
Clinical outcome  
  Crude 30-day mortality 3 (10.7 %)
  Crude 60-day mortality 3 (10.7 %)
Clinical presentation of mono VSB N = 19
  VGS shock syndrome 5 (26 %)
  1. AML acute myeloid leukemia, MDS myelodysplastic syndrome, CML chronic myelogenous leukemia, ALL acute lymphoblastic leukemia, NHL non Hodgkin lymphoma, T-PLL T-cell prolymphocytic leukemia, SAA severe aplastic anemia, CBT cord blood transplantation , rPBSCT related peripheral blood cell transplantation, uBMT unrelated bone marrow transplantation, ANCs absolute neutrophil counts, VCM vancomycin, VSB viridans streptococcal bacteremia, VGS viridans group streptococcus